Upcoming Webinar:Join the webinar on ' Unique ways of participating in agri commodity derivatives' on June 18, 5pm. Register Now!

Buy Ajanta Pharma; target of Rs 2028: Motilal Oswal

Motilal Oswal is bullish on Ajanta Pharma has recommended buy rating on the stock with a target price of Rs 2028 in its research report dated May 03, 2017.

June 08, 2017 / 07:03 PM IST
  • bselive
  • nselive
Todays L/H

Motilal Oswal's research report on Ajanta Pharma

AJP posted in-line sales of INR 4.8b (est. of INR 4.7b). EBITDA margin of 35.9%, adjusted for forex loss accounting for mark-to-market, was significantly better than estimate of 33.8% due to a superior product mix. Higher depreciation on account of commercialization of the Guwahati facility and lower-than-expected other income led to PBT growing at a lower rate than EBITDA.


We remain positive on AJP, given its aggressive filings in the US and better-than-industry growth in India branded sales. We tweak FY18 estimates to factor in better EBITDA margin and a marginal fall in Africa sales. We maintain FY19 estimates and TP of 2,028 on 25x FY19E earnings. Reiterate Buy.

For all recommendations, click here

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.

first published: May 4, 2017 03:46 pm

stay updated

Get Daily News on your Browser